Kamfanin sarrafa magunguna na kasar China, Sinopharm ya fara ajiyar wata allurar rigakafin sabon nau'in kwayar cutar corona (Covid-19).
Dangane da rahoton Global Times daya daga cikin manyan kafafan yada labarai na kasar China, Sinopharm ya fara ajiyar allurar rigakafin corona. An ba da fifiko a cikin ajiyar ga ɗalibai da za su tafi ƙasashen waje daga watan Nuwamba zuwa Janairu. Ma'aikatan gwamnati da ke aiki a kasashen waje da kuma ma'aikatan kiwon lafiya wadanda ke kan gaba wajen yaki da annobar za su sami damar "amfani da gaggawa".
Rahotannin jaridun kasar sun bayyana cewar fiye da mutane dubu 70 sun yi tanadin allurar rigakafin kwayar cutar corona. An kara da cewa Sinopharm zai ba da fifiko a cikin nazarin allurar rigakafi ga birnin Wuhan da Beijing, babban birni kasar inda annobar ta ɓarke.
A cewar Sinopharm, kamfanin wanda ke binciken alluran rigakafi guda biyu a cikin matakin gwajin na 3 wanda ya shafi samfura a cikin kasashe 125, ya sami izinin yin amfani da allurar na gaggawa a ranar 22 ga Yuli.
A kasar China kamfanonin sarafa magunguna kamar su Sinopharm, Sinovac da CanSino suna gudanar da binciken rigakafi tare da hadin gwiwa da cibiyoyi kamar su Makarantar Soja ta Koyon aikin Likita ta Kasar China, Cibiyar Binciken Kwayoyin Cuta ta Wuhan, Cibiyar Binciken Halittu ta Beijing.
Baya ga CoronaVac da kamfanin SinoVac ya samar, alluran rigakafi biyu waɗanda Sinopharm ya samar tare da hadin gwiwar Cibiyar Binciken Kwayoyin Cuta ta Wuhan da kuma Cibiyar Binciken Halittu ta Beijing suna daga cikin bincike mafi nasara.
